A Study of LY3200327 in Healthy Participants

Completed · Phase 1 · Has a placebo group

Conditions studied: Healthy

In brief

The purpose of this study is to look at the safety and tolerability of single doses of LY3200327 when given to healthy male and female participants either by injection under the skin or by drip into a vein. The study will help determine how the drug behaves inside the body and how long it takes to disappear from the body. The study will also look for anti-drug antibodies and how these may affect how LY3200327 acts in your body. The study is expected to last approximately 12 weeks (with screening evaluations up to 4 weeks prior).

Key facts

Study ID

NCT02595736

Run by

Eli Lilly and Company

People needed

52

Starts

2015-11-01

Expected to finish

2016-08-01

Last updated by the study team

2016-09-12

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• At the time of initial screening, in general good health
• First-generation healthy Japanese (age 20 to 65 years) will be included

You may not qualify if…

• Pregnancy or breastfeeding during the study
• Chronic infection
• Treatment with prohibited medications

Where it is running

• Parexel International/ California Clinical Trials — Glendale, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.